1. Home
  2. ZCMD vs IRD Comparison

ZCMD vs IRD Comparison

Compare ZCMD & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZCMD
  • IRD
  • Stock Information
  • Founded
  • ZCMD 2012
  • IRD 2018
  • Country
  • ZCMD China
  • IRD United States
  • Employees
  • ZCMD N/A
  • IRD N/A
  • Industry
  • ZCMD Other Consumer Services
  • IRD
  • Sector
  • ZCMD Real Estate
  • IRD
  • Exchange
  • ZCMD Nasdaq
  • IRD NYSE
  • Market Cap
  • ZCMD 35.3M
  • IRD 36.0M
  • IPO Year
  • ZCMD 2020
  • IRD N/A
  • Fundamental
  • Price
  • ZCMD $1.39
  • IRD $1.13
  • Analyst Decision
  • ZCMD
  • IRD Strong Buy
  • Analyst Count
  • ZCMD 0
  • IRD 1
  • Target Price
  • ZCMD N/A
  • IRD $8.00
  • AVG Volume (30 Days)
  • ZCMD 4.6K
  • IRD 144.3K
  • Earning Date
  • ZCMD 01-01-0001
  • IRD 02-24-2025
  • Dividend Yield
  • ZCMD N/A
  • IRD N/A
  • EPS Growth
  • ZCMD N/A
  • IRD N/A
  • EPS
  • ZCMD N/A
  • IRD N/A
  • Revenue
  • ZCMD $17,406,104.00
  • IRD $8,381,000.00
  • Revenue This Year
  • ZCMD N/A
  • IRD N/A
  • Revenue Next Year
  • ZCMD N/A
  • IRD $29.37
  • P/E Ratio
  • ZCMD N/A
  • IRD N/A
  • Revenue Growth
  • ZCMD 1.01
  • IRD N/A
  • 52 Week Low
  • ZCMD $1.00
  • IRD $0.81
  • 52 Week High
  • ZCMD $5.10
  • IRD $2.71
  • Technical
  • Relative Strength Index (RSI)
  • ZCMD 42.66
  • IRD N/A
  • Support Level
  • ZCMD $1.38
  • IRD N/A
  • Resistance Level
  • ZCMD $1.45
  • IRD N/A
  • Average True Range (ATR)
  • ZCMD 0.07
  • IRD 0.00
  • MACD
  • ZCMD 0.01
  • IRD 0.00
  • Stochastic Oscillator
  • ZCMD 24.27
  • IRD 0.00

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is a Cayman Islands-based provider of healthcare information, education, and training services. It provides services to healthcare professionals and the public in China. It offers online and onsite health information services, healthcare education programs, and healthcare training products, consisting of clinical practice training, open classes of popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: